<DOC>
	<DOCNO>NCT00797706</DOCNO>
	<brief_summary>The purpose study evaluate investigational medicinal product CHRONSEAL intended future treatment chronic venous leg ulcer safe tolerate ulcer size reduction effect administer individual suffer venous leg ulcer .</brief_summary>
	<brief_title>Phase I/II Dose Ranging CHRONSEALÂ® Study Venous Leg Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Leg Ulcer</mesh_term>
	<mesh_term>Varicose Ulcer</mesh_term>
	<criteria>Inclusion criterion ( Runin period ) : 1 . Caucasian male clinically sterile female subject 2 . 40 year old . 3 . Ankle brachial index least 0.6 . 4 . Written inform consent obtain . 5 . Subject legally competent able communicate effectively . 6 . Subject likely cooperate . 7 . Uncomplicated venous ulcer clinical diagnosis . 8 . Full skin ulcer . 9 . Localisation foot knee ( wrist malleoli include ) 10 . Duration least 3 month . 11 . Area 320 cm2 . Exclusion criterion ( Runin period ) 1 . Visible sign infection , black necrosis discharge target ulcer . 2 . More ~20 % slough debridement . 3 . Ulcer location extension either difficult follow treat accord protocol . 4 . Other known etiology target ulcer . 5 . Subject discretion investigator clinically significant finding physical examination vital sign . 6 . Concomitant systemic topical treatment within 14 day prior start study medication antibiotic antiseptic treatment ulcer infection target ulcer . 7 . Concomitant systemic treatment within 14 day prior start study medication immunosuppressive 8 . Concomitant topical treatment within 14 day prior start study medication follow : NSAIDs , aspirin Growth factor , biologically active agent Products contain chlorhexidine , potassium permanganate , iodine silver 9 . Diabetes Mellitus require pharmaceutical treatment . 10 . Comorbidity life expectancy le 6 month . 11 . Comorbidity expect low compliance . 12 . Diagnosed kidney disease 13 . Individuals sensitive study medication component . 14 . Subject receive investigational drug product , enrol investigational drug protocol within period 30 day prior receive first dose study medication . 15 . Known abuse alcohol , drug pharmaceutical . 16 . Diagnosis squamous epithelium carcinoma 17 . Diagnoses serious psychiatric illness may influence study participation . Inclusion criterion ( Randomization ) 1 . Subject likely cooperate . 2 . Ulcer area reduction le 50 % runin period . 3 . Ulcer area 320 cm2 . Exclusion criterion ( Randomization ) 1. &amp; 2 . = Runin period criterion 1 . &amp; 2 . 3 . Subject discretion investigator clinically significant finding vital sign laboratory value . 4.10 . = Runin period criterion 6. , 7. , 8. , 11. , 12. , 13. , &amp; 14</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>